X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TNX-2900 (oxytocin) is a proprietary magnesium (Mg2+)-potentiated formulation of intranasal oxytocin. It is being evaluated for the treatment of Prader-Willi syndrome (PWS) in children and adolescents.
Lead Product(s): Magnesium Potentiated Oxytocin
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
The agreement aims for the potential launch and commercialization of Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets), a centrally acting, non-opioid medication, in the US.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Almac Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 20, 2024
Details:
Tonmya (cyclobenzaprine HCl) is a sublingual product candidate. It is a multifuntional agent with antagonist activity at serotonin2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors. It is being evaluated for the treatment of fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
TNX-1500 is a Fc-modified humanized anti-CD40L monoclonal antibody that interacts with the CD40-ligand, which is being evaluated for the treatment of organ transplant rejection.
Lead Product(s): TNX-1500
Therapeutic Area: Immunology Product Name: TNX-1500
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
TNX-1500 is a Fc-modified humanized anti-CD40L monoclonal antibody that interacts with the CD40-ligand, which is being evaluated for the treatment of organ transplant rejection.
Lead Product(s): TNX-1500
Therapeutic Area: Immunology Product Name: TNX-1500
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Tonmya (cyclobenzaprine HCl) is a sublingual product candidate. It is a multifuntional agent with antagonist activity at serotonin2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors. It is being evaluated for the treatment of fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2024
Details:
The collaboration aims to support Tonix to focus on the Tonmya (cyclobenzaprine HCl), which is a multifunctional agent with potent binding and antagonist activity at the 5-HT2A-serotonergic. It is in development as a daily bedtime treatment for fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Rho
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2024
Details:
Tonmya (TNX-102 SL) is a sublingual tablet formulation of cyclobenzaprine hydrochloride, which is being evaluated for the treatment of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD).
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Psychiatry/Psychology Product Name: Tonmya
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
TNX-102 SL (cyclobenzaprine HCl) is a sublingual product candidate. It is a multifuntional agent with antagonist activity at serotonin2A, α1-adrenergic, histaminergic-H1, and muscarinic-M1 receptors. It is being evaluated in phase 3 clinical trials for the treatment of Fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
Tonix currently intends to use the net proceeds for the preparation of their new drug application relating to TNX-102 SL (cyclobenzaprine hydrochloride) in patients with fibromyalgia.
Lead Product(s): Cyclobenzaprine
Therapeutic Area: Musculoskeletal Product Name: Tonmya
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alliance Global Partners
Deal Size: $144.0 million Upfront Cash: $30.0 million
Deal Type: Public Offering December 21, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
